Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Quantum Computing Inc. heads into its November earnings with one of the most structurally constrained borrow markets on the Nasdaq, a short base that refuses to shrink, and options traders now meaningfully more cautious than at any point in recent months.
The lending picture is stark. Availability has been at 0% for the best part of six weeks, meaning every share in the lending pool is already out on loan. That is the tightest the borrow market has been all year, matching the 52-week low. Yet despite this closed lending pool, estimated short interest has kept rising, adding roughly 7.1 million shares over the past week to reach 31% of free float as of 13 October. Short interest is also up 9.3% over the past month. As noted in this week's earlier note on QUBT, the mechanism is familiar: existing borrows roll and prime brokerage books allow incremental positioning even when headline availability reads zero. The cost to borrow has settled near 11.2%, high by any standard, though it has eased about 28% from its peak a month ago, when it briefly touched 15.5%. Bears who wanted exposure largely secured it at higher carry costs; the current level suggests the pool has stabilised rather than loosened.
Options positioning has shifted in the same direction as the shorts. The put/call ratio has jumped to 0.68, nearly 2.75 standard deviations above its 20-day average of 0.58. That is a meaningful move, and it places current defensive positioning well outside the normal range. The 52-week high on the PCR remains 1.23, so this is not a panic reading, but the directional shift over the past week is clear: options traders are adding downside cover at a pace they have not seen recently. The stock fell 12.6% on the week and 14% over the past month to close at $6.87, which gives those put buyers a live position.
The Street is divided and the data cited here are as of late August, which is worth flagging. Cantor Fitzgerald holds a Neutral with a $10 target, Wedbush sits at Neutral with $12, while Ascendiant Capital raised its Buy target to $32 and Rosenblatt carries Buy at $22. The mean target across the coverage group is around $18.67, implying substantial implied upside from current levels, though with the stock at $6.87 and given the staleness of those targets, readers should weigh that gap against how much has changed since August. The bull case rests on $5.6 million in Q2 revenue (from near zero a year earlier), $1.3 billion in cash with no debt, and the TFLN foundry beginning to contribute. Bears point to a $(11.8) million net loss in the same quarter, competition from IBM, Google, and Microsoft, and forecast cuts to EPS through 2027. The ORTEX short score sits at 84.8, in the highest percentile of the universe, and the days-to-cover based on official FINRA data runs to 8.6 days, reflecting how long it would take shorts to exit at normal volume. The price-to-book multiple has compressed about 16% over the past month, now running just above 1.0, which tells you the market is assigning almost no premium above book value for the growth narrative.
CEO Yuping Huang remains the largest individual holder at just over 10% of shares. His most recent filing, in August, recorded a grant of 584,897 shares rather than an open-market purchase, so it reflects compensation mechanics rather than a discretionary market buy. He also filed a Schedule 13D/A in May, which means he is on the register as an activist-intent holder. The Schedule 13D/G register carries the standard caveat: stakes are as last disclosed and a holder dropping below 5% may not file again. BlackRock added 1.6 million shares in the period to 30 September, bringing its holding to 7.8% of shares, while Penserra Capital Management added 3.6 million shares in the same period, a more aggressive move by a smaller holder. Retail attention, measured by Wikipedia page views and ORTEX stock page traffic, had a z-score of 2.1 in late September, a well-above-average reading that suggests the stock continues to attract significant individual investor interest even as the share price slides.
The next earnings print is scheduled for 13 November, 30 days away. With availability locked at zero, short interest still climbing, options defensiveness at a multi-month high, and a closing stock price now near the same level where directors received their April grants at $6.78, the contest between the bear thesis (loss-making, crowded sector, uncertain path to scale) and the bull case (cash-rich, early in a genuinely new technology curve) will get its next data point then.
See the live data behind this article on ORTEX.
Open QUBT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
